MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10552-021-01527-w

Медицинская библиотека · Cancer causes & control : CCC · 2021

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system.

Eskelinen Tommi, Veitonmäki Thea, Kotsar Andres, Tammela Teuvo L J, Pöyhönen Antti, Murtola Teemu J

СтатьяПеревод в очереди

Аннотация

PURPOSE: We explored renal cell cancer (RCC) survival among users of antihypertensive medication as hypertension is proposed to be a risk factor for RCC and ACE-inhibitors and angiotensin receptor blockers (ARBs) have been associated with improved prognosis of RCC.

METHODS

Finnish cohort of 13,873 participants with RCC diagnosed between 1995-2012 was formed from three national databases. RCC cases were identified from Finnish Cancer Registry, medication usage from national prescription database and co-morbidities from Care Registry of Healthcare. Logistic regression was used to calculate odds ratios for metastatic tumor extent at the time of diagnosis. Risk of RCC specific death after diagnosis was analyzed using Cox regression adjusted for tumor clinical characteristics.

RESULTS

A total of 5,179 participants died of RCC during the follow-up. No risk association was found for metastatic tumor extent for any drug group. ACE-inhibitors, but no other drug group were associated with decreased risk of RCC specific death overall (HR 0.88, 95% CI 0.82-0.95) compared to non-users. In time-dependent analysis high-dose use of ACE-inhibitors (392 Defined Daily Dose (DDD)/year), HR 0.54, 95% CI 0.45-0.66) and ARBs (786.1 DDD/year, HR 0.66, 95% CI 0.50-0.87) associated with improved RCC survival. No information of TNM-classification or tobacco smoking was available.

CONCLUSION

ACE-inhibitors and ARBs in high dose associated with improved RCC specific survival. This may reflect overall benefit of treating hypertension with medication targeting renin-angiotensin system (RAS) system among RCC patients. Further studies are needed to explore the role of RAS in RCC.

Для цитирования: Eskelinen Tommi, Veitonmäki Thea, Kotsar Andres, Tammela Teuvo L J, Pöyhönen Antti, Murtola Teemu J. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system.. Cancer causes & control : CCC. 2021. DOI: 10.1007/s10552-021-01527-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.